Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation
Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), L Rhoda Molife(Institute of Cancer Research), Karin Leunen(Fondazione IRCCS Istituto Nazionale dei Tumori), Michael Friedländer(Prince of Wales Hospital), Anitra Fielding(AstraZeneca (United States)), Shibani Nicum(London Cancer), C. Sessa(Vita-Salute San Raffaele University), Charlie Gourley(Edinburgh Cancer Research), Karin Bowen(Sheba Medical Center), Stan B. Kaye(Institute of Cancer Research)
Unknown
September 1, 2013
Cited by 19
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k